Back to top
more

Amgen Inc: (AMGN)

(Market Close from NSDQ)

 Add to portfolio

Save at Trade

$172.74 USD

172.74
8,528,079

+7.20 (4.35%)

Updated Jul 28, 2015 04:14 PM ET

Volume: 8,528,079

Open: $166.12

Prior Close: $165.54

Zacks Rank : 2-Buy [?]   2      

Style Scores [?] : Growth: C | Value: B | Momentum: B

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Zacks Style Score A
Growth Score A
Value Score A
Momentum Score A
Income Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The three scores are based on the trading styles of Growth, Value, and Momentum.

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Brokerage Reports

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

0 items in cart

AMGEN INC [AMGN]

Reports for Purchase

Showing records 1 - 20 ( 223 total )

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 1

07/28/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 2

07/24/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 3

07/23/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 4

06/22/2015

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 5

06/19/2015

Company Report

Pages: 5

Transferring Coverage

Provider: Robert W. Baird & Co., Inc.

Analyst: SKORNEY B

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 6

06/19/2015

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 7

06/08/2015

Company Report

Pages: 5

Evolocumab Docs Indicate PCSK9s May Not Be as Identical as Thought

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 8

05/25/2015

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 9

05/21/2015

Industry Report

Pages: 5

April Script Data Gives a First Look at Q215

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 10

05/14/2015

Industry Report

Pages: 6

ASCO Abstracts Largely Incremental for Our Names

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 11

04/24/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 12

04/22/2015

Company Report

Pages: 9

Solid Beat but It''s What Comes Next That Has Us Worried

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 13

04/22/2015

Industry Report

Pages: 5

Biotechnology - March Script Data Offers a Last Look at Q115 Commercial Progress

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 14

04/22/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 15

04/21/2015

Industry Report

Pages: 4

Biotechnology -Shaping Up To Be a Busy ASCO Meeting for Many Names on Our List

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 16

04/20/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 17

04/17/2015

Company Report

Pages: 8

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 18

04/14/2015

Company Report

Pages: 10

Corrected: New Survey Points to Significant Share Erosion for ESA Franchise

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 19

04/14/2015

Company Report

Pages: 10

New Survey Points to Significant Share Erosion for ESA Franchise

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 20

04/13/2015

Daily Note

Pages: 15

Biotechnology - Q115 Earnings - a Key Test of Biotech?s Resilience?

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 50.00